Compare CSL & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSL | MEDP |
|---|---|---|
| Founded | 1917 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 16.1B |
| IPO Year | N/A | 2016 |
| Metric | CSL | MEDP |
|---|---|---|
| Price | $326.60 | $604.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 12 |
| Target Price | $386.67 | ★ $479.64 |
| AVG Volume (30 Days) | ★ 402.7K | 203.1K |
| Earning Date | 02-03-2026 | 02-09-2026 |
| Dividend Yield | ★ 1.31% | N/A |
| EPS Growth | N/A | ★ 25.36 |
| EPS | ★ 17.56 | 14.32 |
| Revenue | ★ $5,015,100,000.00 | $2,358,373,000.00 |
| Revenue This Year | $1.01 | $21.43 |
| Revenue Next Year | $2.69 | $11.99 |
| P/E Ratio | ★ $19.13 | $42.52 |
| Revenue Growth | 0.14 | ★ 13.88 |
| 52 Week Low | $293.43 | $250.05 |
| 52 Week High | $435.92 | $626.26 |
| Indicator | CSL | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 49.48 | 66.05 |
| Support Level | $318.99 | $551.00 |
| Resistance Level | $333.87 | $577.40 |
| Average True Range (ATR) | 8.67 | 13.54 |
| MACD | -0.18 | 4.98 |
| Stochastic Oscillator | 31.49 | 85.51 |
Carlisle Companies Inc is a holding company. The company manufactures and sells single-ply roofing products and warranted systems and accessories for the commercial building industry. The company is organized into two segments including Carlisle Construction Materials and Carlisle Weatherproofing Technologies. The company's product portfolio includes moisture protection products, protective roofing underlayments, integrated air and vapor barriers, spray polyurethane foam and coating systems, and others. The majority of the company's revenue comes from the Carlisle Construction Materials segment, and more than half of the total revenue is earned in the United States.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.